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Abstract: Breast cancer is among the most commonly diagnosed cancers in the world, affecting one
in eight women in their lifetimes. The disease places a substantial burden on healthcare systems
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in developed countries and often requires surgical correction. In spite of this, much of the breast
cancer pathophysiology remains unknown, allowing for the cancer to develop to later stages prior
to detection. Many women undergo reduction mammaplasties (RM) to adjust breast size, with
over 500,000 operations being performed annually. Tissue samples from such procedures have
drawn interest recently, with studies attempting to garner a better understanding of breast cancer’s
development. A number of samples have revealed nascent cancer developments that were previously
undetected and unexpected. Investigating these so-called “occult” findings of cancer in otherwise
healthy patients may provide further insight regarding risk factors and countermeasures. Here,
we detail occult findings of cancer in reduction mammaplasty samples provided from a cohort of over
5000 patients from 16 different institutions in Europe. Although the majority of our resected breast
tissue specimens were benign, our findings indicate that there is a continued need for histopathological
examination. As a result, our study suggests that preoperative imaging should be routinely performed
in patients scheduled for RM, especially those with risk factors of breast cancer, to identify and enable
a primary oncologic approach.
Keywords: reduction mammaplasty; occult breast cancer findings; international multicenter study;
breast cancer screening
1. Introduction
Breast cancer is the most commonly diagnosed cancer in women, afflicting 1 in 8 women during
their lifetime [1], and the leading cause of cancer death among women [2]. Even in developing
countries, the incidence of breast cancer is rapidly rising due to increasing life expectancy and dietary
habits, among other risk factors [3]. Due to limited breast cancer awareness, most breast cancer are not
detected at an early stage when treatment is likely to be more successful [4].
In 2018, the incidence rate for breast cancer was over two million worldwide [2]. To date, effective
screening for breast cancer is performed using mammography, but this diagnostic tool is costly and
only feasible in countries with a modern health infrastructure. Clinical breast examination as a low-cost
screening alternative is limited and bears several risks, such as not detecting smaller pathologies
(often overlooking nascent cancers). Recent studies have identified cancerous findings in samples of
otherwise healthy individuals following reduction mammaplasty (RM). RMs are generally electively
performed in women with macromastia to reduce the volume of female breasts and in cases following
oncologic surgery for breast cancer to adjust the size of the breast(s). In 2018, an estimated number of
534,294 breast reductions were performed worldwide [5]. Although such occult cancer findings in RM
specimens [6–9] have been previously reported, information regarding the incidence of breast cancer
found parenthetically in women undergoing breast reduction surgery remains sparse.
The goal of this study was to better determine the incidence of occult breast cancer found during
preoperative workup or the pathology assessment of the reduction specimens using a large retrospective
cohort of women who underwent surgery within an 11-year period (2000–2010). Such information
may allow for the development new screening recommendations. Although the majority of our
resected breast tissue specimens were benign, our findings indicate that there is a continued need for
histopathological examination. In addition to this, the goal of our study was to outline the importance
of developing more feasible screening methods that become commonplace due to this unaddressed
risk of cancer development in female patients.
2. Methods and Patients
With Institutional Review Board (IRB) approval, we performed an international, multicenter
study based on retrospective medical chart review. Twenty-two centers in Germany, Austria, and
South-Tyrol (German-speaking part of Italy) were invited to participate in the study. Sixteen hospitals
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contributed data from 5781 patients who underwent reduction mammaplasty (unilateral or bilateral)
mainly because of macromastia. Eligibility was defined as women who had undergone unilateral
or bilateral reduction mammaplasty for non-oncologic reasons in the years 2000–2010, and of whom
the medical record included, at minimum, the operative report available for review. Women who
had undergone unilateral breast reduction to restore symmetry following contralateral breast cancer
surgery were included. Women with a history of bilateral breast cancer were excluded.
Baseline characteristics of patients were retrieved from the medical records. Family history of
breast/ovarian cancer (BOC) was classified as positive if at least one first-degree relative (FDR) had
a diagnosis of breast and/or ovarian cancer. If no information on any of the baseline characteristics
or affected relatives was found in the medical record, the respective data point was classified as not
available and labeled as missing. Candidates were classified as having undergone preoperative imaging
if the radiology report of at least one breast imaging method (mammography, breast ultrasound,
breast magnetic resonance imaging) from the preoperative period was available in the medical record.
Information on the surgical procedure was attained from the operative report, and information on
pathological workup from the pathology report. Pathologic findings in RM specimens were categorized
as premalignant (atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH)), preinvasive
(ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)), or invasive (ductal carcinoma or
lobular carcinoma).
All data were entered remotely at the participating center using an electronic data capture form
and stored in a central database. Statistical analysis was mainly descriptive. To test for differences
in baseline characteristics between patients with and without preoperative imaging, the t-test was
used for continuous variables and the chi-squared test for categorical variables. The level of statistical
significance was chosen at p < 0.05.
3. Results
The participating centers identified a total of 5781 eligible patients who underwent reduction
mammoplasty between 2000 and 2010. Each center contributed a median number of 323 patients (range:
60–1103 patients). The average age of patients at RM was 38.5 (±13.6) years with a mean body weight of
70.5 (±12.1) kg and a BMI of 25.9 (±4.2) kg/m2. A total of 578 patients (~10%) had a history of unilateral
breast cancer, of which 450 had been invasive carcinomas and 128 in-situ carcinomas. Family history
of breast and/or ovarian cancer in first-degree relatives (FDR) was positive in 112 patients (1.9%).
Baseline characteristics of patients are shown in Table 1.
Pre-operative imaging performed with at least one method (mammogram, breast ultrasound,
breast MRI) was documented for 1618 patients (28%). Patients who had undergone imaging were
on average older (mean age 43.2 years vs. 36.7 years, p < 0.001). The proportion of women who
had preoperative imaging was higher among postmenopausal vs. premenopausal women (40.2% vs.
24.1%), patients with a personal history of breast cancer (47.9% vs. 25.8% in those with no history), and
women who had a family history of BOC (57.1% vs. 33.3%). Patients with imaging had a slightly higher
body weight and lower body height, and higher BMI (Table 1). Notably, of the overall 578 patients in
our study population who had a history of breast cancer, 301 patients (52.1%) had no preoperative
imaging documented. Of the 112 patients with a family history of BOC, 48 patients (42.9%) had
no documented imaging preceding the RM. Overall, 4103 patients (71.0%) had preoperative photo
documentation of the breasts (Table 2).
The most frequently used radiological imaging technique was mammography (1438 patients,
24.9%), followed by breast ultrasound (927 patients, 16.0%) and breast MRI (135 patients, 2.3%).
Among the 1618 patients who had any preoperative imaging, a radiologically suspect finding was
documented for 206 patients (12.7%), and in 21 patients (1.3%) a biopsy-confirmed malignancy was
detected. The indication for surgery in these 21 patients became an oncologic indication, therefore
they were excluded from further analysis. The operative reports of the remaining 5760 patients were
reviewed (Figure 1).
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Table 1. Baseline characteristics of patients (n = 5781).
Preoperative Imaging
Characteristic Total Yes No p-Value *
Age at RM 1, n (%) 5781 (100) 1618 (28.0) 4163 (72.0)
Median (range), years 38 (14–79) 43 (15–79) 36 (14–78)
Mean (SD), years 38.5 (13.6) 43.2 (12.8) 36.7 (13.4) <0.001
Body weight, n (%) 3741 (64.7) 1268 (33.9) 2473 (66.1)
Median (range), kg 69 (41–165) 70 (45–158) 69 (41–165)
Mean (SD), kg 70.5 (12.1) 71.4 (12.3) 71.4 (12.3) 0.003
N/A 2040 (35.3) – –
Body height, n (%) 3712 (64.2) 1254 (33.8) 2458 (66.2)
Median (range), cm 165 (133–197) 165 (145–197) 165 (133–195)
Mean (SD), cm 164.9 (6.5) 164.7 (6.6) 165.0 (6.5) 0.005
N/A 2068 (35.8) – –
BMI (kg/m2), n (%) 3692 (63.9) 1243 (33.7) 2449 (66.3)
Median (range), kg/m2 25 (14–58) 27 (16–52) 25 (14–58)
Mean (SD), kg/m2 25.9 (4.2) 26.3 (4.3) 25.7 (4.2) <0.001
N/A 2089 (36.1) – –
Menopausal status, n (%)
Premenopausal 3295 (57.0) 795 (24.1) 2500 (75.9)
Postmenopausal 810 (14.0) 326 (40.2) 484 (59.8) <0.001
N/A 1676 (29.0)
Personal history of breast cancer, n (%)
No 5203 (90.0) 1341 (25.8) 3862 (74.2)
Yes 578 (10.0) 277 (47.9) 301 (52.1) <0.001
in situ 128 (2.2) 54 (42.2) 74 (57.8)
Invasive 450 (7.8) 223 (49.6) 227 (50.4)
Family history of breast and/or
ovarian cancer in FDRs 2, n (%)
Positive 112 (1.9) 64 (57.1) 48 (42.9)
Negative 2096 (36.3) 697 (33.3) 1399 (66.7) <0.001
N/A 3573 (61.8) – –
Abbreviations: RM, reduction mammoplasty; SD, standard deviation; N/A, not available; BMI, body mass index;
FDR, first-degree relative. 1 Age calculated as year of surgery minus birth year; 2 First-degree relatives are mother or
sister. No cases of BC were reported in the father, brother, daughter, or son of any patient undergoing RM; * p-value
for difference between patients with and without imaging (t-test for continuous, chi2 for categorical variables).
Table 2. Preoperative imaging (n = 5781).
Radiologic Procedure * n %
Mammogram 1438 24.9
Breast ultrasound 927 16.0
Breast MRI 135 2.3
Any preoperative imaging 1618 28.0
Suspect finding 206 12.7




Abbreviation: MRI, magnetic resonance imaging; * Patients who had more than one radiologic procedure are
counted in each category.
In total, 5027 patients underwent bilateral and 733 patients had unilateral reduction mammoplasties.
The most frequent indication for this surgical procedure was macromastia (n = 4336 patients, 75.3%;
Table 3). Other indications were acquired asymmetry (9.5%), developmental asymmetry (8.5%), breast
ptosis (4.2%) and other reasons (3.8%). The applied surgical techniques and their frequencies are listed
in Table 3.
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Figure 1. CONSORT diagram of the patient flow through preoperative diagnostic and surgical
intervention in the study.







Acquired asymmetry 545 9.5
Developmental asymmetry 490 8.5
Breast ptosis 241 4.2
Other 219 3.8
Surgical technique 2
Superior pedicle techniques 2762 48.0
Inferior pedicle techniques 1345 23.4
Vertical scar technique 665 11.5
Central pedicle technique 296 5.1
Medio cranial pedicle techniques 241 4.2
Short scar technique 143 2.5
Free nipple 93 1.6
Round block 83 1.4
Reconstructive interventions (implants, corrections) 60 1.0




Orientation marking of specimen
Yes 34 0.6
No 5726 99.4







Invasive Cancer 9 0.2
No 5244 99.2
Weight of specimen n = 9415 * 87.3
Median (range), g 496 (5–6800)
Mean (SD), g 548 (342)
Abbreviation: SD, standard deviation; 1 In 71 patients undergoing bilateral RM, the indication was different for each
breast. These patients were counted in each category; 2 In 89 patients undergoing bilateral RM, a different technique
was applied on each breast. These patients were counted in each category; * From a total of 10,787 operated breasts
(5027 patients had bilateral RM and 733 patients had unilateral RM), weight of tissue specimen was available of
9415 breasts.
A pathological report of the specimen workup was available for 5284 of the 5760 operated patients
(91.7%). The specimen weight ranged from 5 g to 6800 g, with a median weight of 496 g. Suture marking
was documented in 34 (0.6%) of patients. In 40 of 5284 patients (0.8%), a pathological finding was
reported: 13 patients with premalignant lesions, 18 patients with preinvasive cancer, and 9 patients
(0.2%) with invasive breast cancer (Table 3).
Of the 13 patients with premalignant histologic findings, 7 were diagnosed with ADH (average
age: 49 [±43–62] years) and 6 with ALH (average age: 48.5 [±41–65] years). In this group, 2 patients had
been diagnosed with contralateral breast cancer 1 year and 3 years prior to the reduction mammaplasty;
none had a positive breast/ovarian cancer family history. Breast imaging prior to the surgery was
documented for 3/13 patients (Table 4).
In the group of 18 patients with preinvasive histology findings, 14 were diagnosed with DCIS
(average age: 54.5 [±23–65] years) and 4 with LCIS (average age: 57.5 [±44–66] years). Four patients
had a history of contralateral breast cancer, and two patients with DCIS had a positive family history
of BOC. Seven of 18 patients received a preoperative mamma diagnostic. Seven of 18 patients received
a preoperative mamma diagnostic.
There were six patients with ductal (average age: 54.5 [±46–64] years) and three patients with
lobular (average age: 50 [±44–53] years) invasive cancer findings. One patient had a history of
contralateral breast cancer and one patient a history of contralateral DCIS. Six of the nine patients in
whom invasive cancer was detected received a preoperative mamma diagnostic.
Patients with pathological findings in their breast specimens showed an increased median age
(51 years) compared to the median age of the total patient population of this study (38 years).
Detailed information on the baseline characteristics of patients with pathological findings can be
found in Table 4.
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Abbreviations: ADH, atypical ductal hyperplasia; ALH, atypical lobular hyperplasia; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; BC, breast cancer; MG, mammogram;
US, breast ultrasound; MRI, breast magnetic resonance imaging; RM, reduction mammoplasty; N/A, not available; 1 Patients with a history of contralateral cancer were allowed in the
study; 2 Family history was considered positive if the patient had at least one first-degree-relative affected with breast and/or ovarian cancer; 3 Listed are exams of which a radiology report
was available in the patient medical record. A ‘+’ denotes a suspect finding, a “−” denotes a negative result in the written report; * In 6 patients the pathology was found bilaterally:
ADH (2 patients), DCIS (3 patients), LCIS (1 patient).
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4. Discussion
Breast cancer found parenthetically at the time of reduction mammaplasty is uncommon. In this
large multicenter study, a pathological finding was detected in 0.8% of patients during workup of the
RM specimen, including 0.2% patients with occult invasive breast cancer, confirming a low incidence of
breast cancer detected during RM. Older patients were more likely to have a diagnosis of incidentally
found breast cancer, though their median age (51 years) was lower than that of the overall breast
cancer population (median ~62 years), which is explained by the younger age structure of the study
sample [10].
Our study of 5781 women represents a large cohort of patients who underwent reduction
mammaplasty. The rate of incidentally found breast cancer was consistent with that reported in prior
literature (0.06–4.5%) [7,8,11,12].
Breast imaging prior to surgery was performed in 28% of our patients (n = 1618), with 21 patients
having been diagnosed with breast cancer by confirmatory biopsies following imaging. In four of
the nine patients with occult invasive cancer, the preoperative screening imaging revealed abnormal
finding using radiological imaging, but no biopsy was reported, thus the patients underwent plastic
surgery (i.e., non-oncologic surgery). Of 27 patients with occult invasive or pre-invasive cancer, only
50% had preoperative screening. Overall, no preoperative screening was documented for the majority
of patients (72.0%) undergoing RM. In particular, roughly half of those with a personal or family
history of breast cancer did not have preoperative breast screening documented.
In the collective of patients undergoing breast reduction surgery, neoplastic changes of breast
tissue are typically not primarily expected. However, breast cancer is the most common malignant
cancer in women [2] and the presence of occult breast cancer in RM specimens has been described
before [7,8,11,12]. In previous reports of reduction mammoplasty, the presence of a contralateral
breast cancer was found to be a major risk factor for the presence of occult carcinoma [12–14].
Preoperative radiologic evaluation is an important tool to reduce the number of carcinomas detected
by chance during RM. In young patients, the sensitivity of conventional mammography, especially in
patients with very dense breasts, is reduced [15,16]. A higher accuracy for breast cancer detection by 3D
digital mammography compared to the conventional technique, especially in woman under 50 years
of age with dense fibro-glandular tissue could be shown [17]. Adjunctive breast-ultrasound has shown
increased screening sensitivity, though false-positives are common [18]. Patients with a known elevated
familial risk to develop breast cancer benefit from a significantly higher sensitivity of MRI screening
compared to mammography even if combined with ultrasound diagnostics [19]. Campbell et al.
analyzed the role of preoperative mammography in women seeking reduction mammoplasty and
noted a high incidence of false-positive results, without malignant findings in the specimen [20].
Yet, we believe there is a need for preoperative screening prior to RM, particularly in women with
risk factors such as a personal or family history of breast cancer. The choice of screening method would
follow the recommendations in established guidelines. Knowledge of and following evidence-based
cancer screening guidelines should be mandatory for effective screening and every performing plastic
surgeon. Selber et al. found that only two-thirds of breast surgery performing plastic surgeons were
familiar with the American Cancer Society Breast Cancer Screening Guidelines, and fewer than half
reported concordant practices [21]. Among other recommendations, these guidelines suggest all
women at average risk for breast cancer should begin having yearly mammograms by the age of 45
and can change to having mammograms every other year beginning at age 55 [22]. Women should
have the choice to start screening with yearly mammograms as early as age 40 if they want to. Further,
women who are at high risk for breast cancer based on certain factors should get a breast MRI and a
mammogram every year, typically starting at age 30.
In our study, of the overall 578 patients who had a history of breast cancer, 301 patients (52.1%)
had no preoperative imaging documented. Of the 112 patients with a family history of breast/ovarian
cancer in first-degree relatives, 48 patients (42.9%) had no documented imaging preceding the RM.
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Taken the American Cancer Society Breast Cancer Screening Guidelines into consideration, we suggest
that this number is still too low when performing RM.
Our study benefits from a large sample size of nearly 6000 RM patients that stems from an
international, multicenter approach. A significant number of patients had no documented radiological
imaging prior to the RM. We assume that some patients had their screening at peripheral institutions
and while screening results, presumably negative, may have been known to the surgeons, they were
not documented in the medical record and were thus assumed to be not done for the present study.
For those patients who had pre-operative imaging, we do not have data on the time of imaging relative
to surgery. However, since the study data were collected by reviewing medical records, we make
the assumption that if the radiological report was found in the patient’s chart, the imaging was
performed close to the date of surgery. The pathological report was not found in 8.3% of the patient
medical records that were reviewed. Therefore, the number of patients of whom the pathology report
was available was used as the denominator when estimating the incidence of pathologic findings.
For several patients, the weight of the surgical sample was only of few grams, possibly such small
specimens were intended as representative samples. It is also unknown how much of the breast tissue
was histopathologically examined, especially if the reduction sample was large. Both situations pose
the risk that some tissue abnormalities went undetected and could lead to an underestimation of the
incidence of occult findings, but we believe the difference would be minimal and would not impact the
results of our study.
Our study did not compare whether there was a difference in the discovery rate of cancer according
to the method of RM. Rietjens et al. did not find any difference in the discovery rate between superior
or inferior pedicle mammaplasty [23]. Unfortunately, we do not have follow-up date of patients to
determine the incidence of post-RM breast cancer and relate this to the preoperative screening and
completeness of pathological workup.
In conclusion, a large proportion of RM patients are not screened before undergoing RM and
undetected breast pathology is found, albeit with low incidence, in RM specimens. Preoperative imaging
should be routinely performed in patients scheduled for RM, especially those with risk factors of breast
cancer, to identify and enable a primary oncologic approach.
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